【九源基因:聚乙二醇化人粒细胞刺激因子注射液获批上市】九源基因公布,其聚乙二醇化人粒细胞刺激因子注射液已获国家药品监督管理局批准上市。该注射液用于治疗成年非髓性恶性肿瘤患者,可降低相关感染发生率。其由人粒细胞刺激因子与 20KD 聚乙二醇交联并经纯化获得,具有诸多优点。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.